Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
Incyte (INCY) Weakness Seen Related to OPZELURA Sample 'Texture Issues' - Mizuho
November 2, 2021 11:02 AM EDTMizuho Securities analyst Mara Goldstein weighed in on Incyte (NASDAQ: INCY) following Q3 results and its earnings call. The analyst believes the weakness is likely related to management's comment on a texture issue associated with OPZELURA' (ruxolitinib cream) samples for atopic dermatitis (AD) and is under investigation... More
Incyte (INCY) Tops Q3 EPS by 46c
November 2, 2021 7:16 AM EDTIncyte (NASDAQ: INCY) reported Q3 EPS of $1.18, $0.46 better than the analyst estimate of $0.72. Revenue for the quarter came in at $813 million versus the consensus estimate of $738.52 million.
... More